Can chronic peripheral immune activation promote neuroinflammation and contribute to cognitive decline?

Chronic peripheral immune activation is biologically and clinically relevant to neuroinflammation and cognitive decline, particularly in aging and the Alzheimer disease spectrum. The evidence supports a linked pathway, while its precise causal contribution in individual patients remains unresolved.

Clinical and longitudinal evidence

• In a 41-person MCI-to-Alzheimer cohort, higher anterior-temporal microglial PET signal ([¹¹C]PK11195) predicted faster cognitive decline (standardized β −0.47; p=0.002). Greater whole-cortex TSPO binding has also predicted worsening global cognition in Alzheimer disease.
• In prospective Alzheimer disease observations, acute systemic inflammatory events were associated with approximately doubled cognitive-decline rates over 6 months, while persistently elevated baseline TNF-α predicted roughly fourfold faster decline.
• CSF YKL-40, sTREM2, and GFAP, and plasma GFAP in some longitudinal studies, support involvement of glial/inflammatory biology across preclinical through symptomatic disease. These markers reflect different processes and are not interchangeable.

Mechanistic evidence

• Peripheral inflammatory signaling can activate brain endothelial cells and microglia, including endothelial amplification of microglial NF-κB signaling.
• Chronic low-grade inflammation in experimental models disrupts blood–brain and blood–CSF barrier integrity, increasing CNS exposure to inflammatory mediators, myeloid-cell influx, and microglial changes.
• In aging/Alzheimer-relevant models, inflammation impairs microglial amyloid-β phagocytosis and amyloid-β clearance. APP-transgenic mice show greater central IL-6 elevation and barrier permeability after systemic LPS than wild-type animals.

Interpretation

• Blood inflammatory markers are not reliable proxies for central inflammation: paired blood–CSF inflammatory-marker correlation was low overall (r=0.21). TSPO-PET is also not cell-specific, and its prognostic findings are heterogeneous.

Bottom line

• Chronic peripheral immune activation can plausibly promote neuroinflammation, and neuroinflammatory activity is associated with faster cognitive decline. This is a supported, moderate-confidence mechanistic and prognostic framework—not proof that inflammation alone causes decline or a standalone guide to treatment.